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CASE REPORT
FATAL OUTCOME OF INFECTION BY DENGUE 4 IN A PATIENT WITH THROMBOCYTOPENIC 
PURPURA AS A COMORBID CONDITION IN BRAZIL
Frederico Figueiredo AMÂNCIO(1), Maira Alves PEREIRA(2), Felipe Campos de Melo IANI(2), Lorena D’ANUNCIAÇÃO(2), Jorge Luís Carvalho de ALMEIDA(3),  
Janer Aparecida Silveira SOARES(4), Marcela Lencine FERRAZ(5), Thiago Cardoso VALE(6), José Roberto LAMBERTUCCI(1) & Mariângela CARNEIRO(1,7)
SUMMARY
Dengue is currently a major public-health problem. Dengue virus (DENV) is classified into four distinct serotypes, DENV 1-4. 
After 28 years of absence, DENV-4 was again detected in Brazil in 2010 in Roraima State, and one year later, the virus was identified 
in the northern Brazilian states of Amazonas and Pará, followed by Rio de Janeiro and São Paulo. In Minas Gerais, the first confirmed 
case of DENV-4 occurred in the municipality of Frutal in 2011 and has now been isolated from a growing number of patients. 
Although DENV-2 is associated with the highest risk of severe forms of the disease and death due to the infection, DENV-4 has also 
been associated with severe forms of the disease and an increasing risk of hemorrhagic manifestations. Herein, the first fatal case of 
confirmed DENV-4 in Brazil is reported. The patient was an 11-year-old girl from the municipality of Montes Claros in northern Minas 
Gerais State, Brazil. She had idiopathic thrombocytopenic purpura as a comorbid condition and presented with a fulminant course of 
infection, leading to death due to hemorrhagic complications. Diagnosis was confirmed by detection of Dengue-specific antibodies 
using IgM capture enzyme-linked immunosorbent assay and semi-nested RT-PCR. Primary care physicians and other health-care 
providers should bear in mind that DENV-4 can also result in severe forms of the disease and lead to hemorrhagic complications and 
death, mainly when dengue infection is associated with coexisting conditions.
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INTRODUCTION
Dengue is currently a major public health problem, having become 
the most significant vector-borne viral disease worldwide. Approximately 
two billion people live in risk areas, consisting primarily of tropical and 
subtropical developing countries11. The number of countries reporting 
dengue virus (DENV) cases has increased dramatically in the past decades 
as a reflection of the expanding habitat of the vector Aedes spp., the 
poorly planned urbanization of many cities in developing countries, an 
increased number of susceptible human hosts, and the rapid spread of 
DENV serotypes through global human travel networks26.
DENV is classified into four distinct serotypes (DENV 1-4). DENV-4 
was not detected in Brazil for 28 years after the first clinical and laboratory 
reports of dengue fever cases in Roraima State during 1981-198222. 
Since then, no additional cases have been reported in the country until 
the reemergence of DENV-4 in Boa Vista, Roraima State, in 20101,18,27. 
Following those first recent detections of DENV-4 in Brazil, the virus was 
identified in the northern Brazilian states of Amazonas and Pará20. In the 
Southeast, the first episode of the disease occurred in the state of Rio de 
Janeiro in 201119. The first isolations of DENV-4 in São Paulo occurred 
in February and March of 2011, and both patients (a 31-year-old woman 
and a 49-year-old man) made complete recoveries23. 
The four serotypes of dengue virus have been reported in Minas 
Gerais State. In Minas Gerais, DENV-4 was previously reported 
and confirmed in the municipality of Frutal in 2011 (unpublished 
observations). In 2012, DENV-4 was isolated from a growing number of 
patients in various counties in the state of Minas Gerais. Up to July 2013, 
there are no published reports of severe DENV-4 cases. To the best of our 
knowledge, we herein present the first fatal case of confirmed DENV-4 
infection in Brazil. The patient lived in Montes Claros, a municipality 
located in the northern region of the state (16°44´S 43°51´W; 361,971 
inhabitants). 
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CASE REPORT
An 11-year-old girl with a past relevant medical history of idiopathic 
thrombocytopenic purpura presented on the 26th of December 2012 
complaining of a two-day fever, retro-orbital pain, arthralgia and malaise. 
Upon examination, she was febrile (39.5 °C), with a maculopapular rash 
and oropharyngeal hyperemia. The initial blood hematocrit results and 
platelet count were unrevealing, the patient did not have low platelet 
counts or plasma leakage (Table 1). She was treated with analgesics 
(acetaminophen) and oral hydration. The initial suspicion was dengue. 
The following day, she returned to the hospital with persistent fever and 
received dipyrone, paracetamol and amoxicillin due to a presumptive 
diagnosis of bacterial pharyngitis. On the fifth day of symptoms, she was 
readmitted to the hospital with a high axillary temperature (41 °C), and 
the disease evolved with dizziness, dyspnea, hiccups and eight episodes 
of vomiting combined with nasal and gingival bleeding. In the emergency 
room, resuscitation was initiated with an isotonic crystalloid solution 
combined with a vasopressor (dopamine). She was transferred to the 
intensive care unit with severe systemic signs of refractory shock. Upon 
a physical examination, she had an enlarged palpable liver. Due to altered 
consciousness and respiratory distress, the patient required orotracheal 
intubation. Five units of platelets, 1200 mL of fresh frozen plasma and 
300 mL of red blood cells were transfused due to a low platelet count 
and low hematocrit (Table 1).
Despite intensive care, the patient deteriorated and became 
hypotensive, hypothermic and died of hemorrhagic shock, possibly 
secondary to gastrointestinal bleeding, on the sixth day after the start of 
symptoms. Further history revealed that all of her family had a dengue-
like clinical picture (myalgia, fever and rash). Her mother had symptom 
onset on December 13th, her father on the 15th and her grandmother on 
the 20th. There were no recent trips and no contact with natural waters, 
tick bites or excrement from rats or other animals. Serological tests for 
yellow fever, hepatitis A and B, leptospirosis and rickettsia were negative. 
Blood cultures isolated no bacteria. Dengue-specific antibodies were 
detected in the plasma using an IgM and IgG capture enzyme-linked 
immunosorbent assay (PanBio, Brisbane, Australia). The sample was 
collected on the 29th of December 2012, on the fifth day of symptoms. 
DENV-4 was confirmed by conventional semi-nested reverse transcriptase 
polymerase chain reaction (semi-nested RT-PCR), which was performed 
according to LANCIOTTI et al.13 (Fig. 1).
DISCUSSION
This is the first published case of a confirmed fatal DENV-4 infection 
in Brazil. Although numerous prospective studies have considered 
DENV-2 as the dengue virus with the highest risk for severe forms of the 
disease and death, DENV-4 has also been associated with severe forms 
of the disease17 and an increasing risk of hemorrhagic manifestations12. 
Among 29 laboratory-confirmed cases of dengue hemorrhagic fever 
during an outbreak in Puerto Rico in 1986, DENV-4 was isolated from 
eight patients7. In India, two cases of severe DENV-4 were reported in 
2009 and 2010, one of them fatal4. In Brazil, up to July 2013, there are 
no published reports of severe dengue cases or death caused by DENV-4.
Serotype is not the only factor that influences dengue severity. Several 
epidemiologic studies have shown that the risk of severe disease is higher 
during a secondary dengue virus infection6,10,28. Our patient had positive 
dengue IgM and IgG antibodies on the fifth day of symptoms. VAZQUEZ 
et al., found that Panbio Dengue IgM and IgG assays are highly accurate 
in classifying dengue infection types (primary or secondary infections). 
According to the author, patients with positive IgM and IgG antibodies 
could accurately have been classified as having a secondary infection 
Table 1
Laboratory data 
Date 26/12/2012 29/12/2012 (19:09)
29/12/2012 
(21:47)
Hemoglobin (g/dL) 12.6 8.6 6.7
Hematocrit (%) 38.2 25.3 19.8
White blood cells (x103/
mL)
3.8 30.6 36.2
Neutrophils % 74 47 44
Bands % 8 33 36
Lymphocytes (%) 13 16 15
Monocytes (%) 5 3 4
Eosinophils 0 1 1
Platelet count (x103/mL) 163 32 42
INR* 2.11
Sodium (mEq/L) 136 134
Potassium (mEq/L) 4.3 5.2
Urea (mg/dL) 64 42
Creatinine (mg/dL) 2.32 1.57
INR: International normalized ratio. 
Fig. 1 - Agarose (2%) gel analysis of semi nested RT-PCR products from Dengue virus. Lane 
1: 100bpDNA ladder (Bio Labs); Lane 3: negative control; Lane 4: positive control DENV-1 
(482bp); Lane 5: positive control DENV-2 (119bp); Lane 6: positive control DENV-3 (290bp); 
Lane 8 and 9: sample patient (392bp); Lane 10: positive control DENV-4 (392bp).
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based on the Panbio assay29. A secondary dengue infection may partially 
explain the severity of the case report here.
Age has also been associated with severity and poor prognosis. 
Previous studies have pointed out that children younger than 14 years 
old were at a higher risk of severe dengue9,21 but these findings were not 
replicated by other researchers. The current WHO30 and the Brazilian 
guidelines2 for dengue management consider, respectively, infancy and 
children younger than two years old as groups requiring special care. 
This topic still remains open and needs further studies to define the exact 
age group at the highest risk. 
Apart from serotype, secondary infection, age and a presence of 
comorbidities are reported as risk factors for severe dengue. To name 
a few, sickle cell anemia, autoimmune diseases, asthma, hypertension, 
uremia and diabetes mellitus have already been linked to poorer outcome 
and severe forms of the disease3,5,8,16. Their presence renders a more 
complex dengue management and increases the risk of complications30. 
Idiopathic thrombocytopenic purpura or immune thrombocytopenic 
purpura in children is an immune-mediated thrombocytopenia, usually 
benign, with an average recovery time of three months. A small number 
of children will have recurrent acute thrombocytopenia24. In 1997, 
RODRÍGUEZ-ANGULO et al. reported the case of a 35-year-old man 
with immune thrombocytopenic purpura who developed dengue with 
hemorrhagic manifestations; the authors suggested that dengue could 
have exacerbated the chronic immune process producing more severe 
thrombocytopenia and bleeding25. 
In this report, age, the presence of immune thrombocytopenic purpura 
and the hemorrhagic manifestations (nasal, gingival and intestinal 
bleeding) might have contributed to the poor prognosis and death. 
There was no evidence of plasma leakage and hemorrhagic shock was 
the probable mechanism of death, as indicated by an abrupt drop in the 
hemoglobin count and massive digestive bleeding. It is difficult to define 
exactly if dengue infection was the determinant factor for the patient´s 
death. In our opinion, dengue was the underlying cause of death as the 
infection initiated the train of events leading to the death. So the patient 
might have died from dengue instead of dying with dengue. 
Despite the negative blood cultures, a diagnosis of concomitant 
bacterial infection cannot be discarded in the present case. LEE et al. 
have reported concurrent bacteremia in 5.5% of the patients with severe 
dengue14. According to the author, patients with bacteremia had higher 
frequencies of gastrointestinal bleeding and altered consciousness, as 
observed in our report. The leukocytosis may have been secondary to 
a bacterial infection; nevertheless, leukocytosis can also occur in the 
presence of hemorrhagic shock as a consequence of stressful stimuli. 
LEE et al. observed leukocytosis in six of nine patients, who died from 
dengue, suggesting that massive bleeding and bacteremia were the major 
causes of leukocytosis in dengue patients15. Regardless of the cause, 
the authors have suggested that leukocytosis is associated with poor 
prognosis in dengue patients and this laboratory abnormality could be 
useful as a warning sign15. The authors still suggest that, especially in 
dengue patients with altered consciousness and leukocytosis, antibiotics 
should be empirically initiated until a bacterial infection can be excluded. 
In Brazil, the dengue hyperendemicity and recent circulation of 
DENV-4 may partially explain the increase in severe cases and associated 
deaths. This case shows that primary care physicians and other healthcare 
providers should bear in mind that any serotype, including DENV-4, can 
cause severe forms of disease and lead to hemorrhagic complications 
and death, mainly when dengue infection is associated with coexisting 
conditions.
RESUMO
Óbito por dengue 4 no Brasil em paciente com púrpura 
trombocitopênica idiopática
Dengue é atualmente um importante problema de saúde pública. O 
vírus da dengue (DENV) é classificado em quatro sorotipos distintos, 
DENV 1-4. Após 28 anos de ausência, o DENV-4 foi detectado 
novamente no Brasil em 2010 no Estado de Roraima, e um ano depois, 
o vírus foi identificado em outros estados do norte do país, Amazonas 
e Pará, seguido pelos estados do Rio de Janeiro e São Paulo. Em Minas 
Gerais, o primeiro caso confirmado de DENV-4 ocorreu no município 
de Frutal em 2011 e, desde então, o sorotipo foi isolado em um número 
crescente de pacientes. Apesar do DENV-2 estar associado a um maior 
risco de formas graves e morte, o DENV-4 também tem sido associado 
a casos graves e a risco aumentado de manifestações hemorrágicas. 
Neste relato, descrevemos o primeiro caso fatal confirmado por DENV-
4 no Brasil. A paciente era uma menina de 11 anos do município de 
Montes Claros, no norte de Minas Gerais, Brasil. Apresentava púrpura 
trombocitopênica idiopática e evoluiu de forma fulminante durante a 
infecção por dengue, com óbito associado a complicações hemorrágicas. 
O diagnóstico foi confirmado pela detecção de anticorpos IgM específicos 
para dengue, por método imunoenzimático, e por semi-nested RT-PCR. 
Médicos e outros profissionais de saúde devem estar cientes que infecções 
por DENV-4 também podem resultar em formas graves da doença com 
complicações hemorrágicas e óbito, principalmente em pacientes com 
comorbidades.
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